Company Profile
Foghorn Therapeutics Stock Price, News & Analysis
Company overview
Business overview
Foghorn Therapeutics is a biopharmaceutical company focused on pipeline execution and catalyst-driven growth, with investors tracking how data, regulatory milestones, and launch timing reshape the investment case.
Geographic Base and Sector Classification
Headquartered in the United States and listed on NASDAQ, Foghorn Therapeutics is followed within the biopharmaceutical universe for its exposure to pipeline and commercialization catalysts.
Business Model Characteristics
Foghorn Therapeutics follows a pipeline-led model where clinical readouts, filing updates, and program expansion determine how the market underwrites the story.
Position Within the Biotechnology Landscape
Compared with more mature healthcare names, Foghorn Therapeutics sits on the development side of the biotech landscape, where catalyst timing can reprice the stock quickly.
Why the stock is moving
FHTX is trading with a steady catalyst profile while investors wait for the next headline that changes the story.
Future catalysts
Foghorn’s next three months are about its chromatin-regulation oncology programs and any data that show the platform can still produce differentiated human results. The market will care most about whether the synthetic-lethality thesis can keep moving forward.
Recent news
The five most recent feed items are shown below in reverse chronological order.
- 01
Foghorn Therapeutics Provides First Quarter 2026 Financial and Corporate Update
Source: Foghorn Therapeutics
- 02
Foghorn Therapeutics Provides Third Quarter 2025 Financial and Corporate Update
Source: Foghorn Therapeutics
- 03
Foghorn Therapeutics to Participate in the 8th Annual Evercore Healthcare Conference
Source: Foghorn Therapeutics
- 04
Foghorn Therapeutics Highlights January Equity Financing, Program Progress and Strategic Objectives for 2026
Source: Foghorn Therapeutics
- 05
Foghorn Therapeutics Announces Closing of $50 Million Registered Direct Financing at a 30% Premium
Source: Foghorn Therapeutics
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.